Replibio (300119.SZ) plans to transfer 48.4213% of the equity of its subsidiary Zhong'an Biotech for 115 million yuan.

Zhixun News of Securities Times APP, RepBio (300119.SZ) announced that the company plans to transfer 48.4213% equity of its controlling subsidiary Hunan Zhong'an Biopharmaceutical Co., Ltd. ("Zhong'an Biopharm") to Jiangxi Twins Bio-technology Co., Ltd. ("Twins Bio"), this transaction involves the investment project "Zhong'an Biopharm Reform and Expansion Project" implemented by Zhong'an Biopharm. The transfer price of this transaction is 115 million yuan. After the completion of this transaction, the company will hold 20% equity of Zhong'an Biopharm, and Zhong'an Biopharm will no longer be included in the company's consolidated financial statements.